Question 1

What do medical sources say about Atomoxetine (Strattera) during pregnancy?

Accepted Answer

1st Trimester: MotherToBaby reports that four human studies have not suggested more birth defects, but most used prescription records that cannot confirm the medicine was taken. A 2026 Norwegian registry study found higher miscarriage odds with atomoxetine prescriptions (aOR 2.34, 95% CI 1.41-3.89), while a corrected review combining atomoxetine with methylphenidate did not find a statistically significant increase. The STRATTERA label states, "Available published studies with STRATTERA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes." Its boxed warning states, "STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies." It further says, "All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes." Ask your provider about your situation. 2nd Trimester: MotherToBaby reports that one study of 453 people who filled atomoxetine prescriptions during the first 20 weeks found no increased chance of placental abruption, a small-for-gestational-age baby, preterm delivery, or preeclampsia; prescription records cannot confirm the medicine was taken. A 2026 health-record study of 405 atomoxetine users reported higher adjusted odds of fetal growth restriction and large-for-gestational-age birth, although its unadjusted percentages were similar to controls and it did not report trimester-specific results. The STRATTERA label states, "Available published studies with STRATTERA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes." Its boxed warning states, "STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies." It further says, "All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes." Ask your provider about your situation. 3rd Trimester: MotherToBaby does not report atomoxetine-specific findings for later pregnancy; a 2026 Nordic study of 11,075 pregnancies found late use of ADHD medicines overall was not linked to a statistically significant rise in preterm birth (aHR 1.15, 95% CI 0.95-1.39), though the estimate rose with each 30 days of late exposure, and atomoxetine-specific late-pregnancy results were not reported. A 2025 Swedish cohort included 209 atomoxetine-exposed children and found no increased neurodevelopmental-disorder estimate, but the atomoxetine result was imprecise and not specific to late exposure. The STRATTERA label states, "Available published studies with STRATTERA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes." Its boxed warning states, "STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies." It further says, "All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes." Ask your provider about your situation.

Question 2

What do medical sources say about Atomoxetine (Strattera) while breastfeeding?

Accepted Answer

LactMed reports that a study of 10 mothers found a relative infant dose of 0.19% at an adjusted 80 mg daily dose, and the mothers reported no suspected effects in their 11 infants. A 2026 single-patient milk study estimated a combined relative infant dose of 0.145% for atomoxetine and its metabolite; it did not report infant outcomes. MotherToBaby says there are no breastfeeding studies, and the STRATTERA label says it is not known whether the medicine passes into milk, although two milk-transfer studies are now available. The label's boxed warning states, "STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies." It further says, "All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes." Ask your provider about your situation.

Question 3

Where do sources disagree on Atomoxetine (Strattera) in pregnancy or breastfeeding?

Accepted Answer

Miscarriage evidence A 2026 Norwegian registry study reported higher miscarriage odds with atomoxetine prescriptions (aOR 2.34, 95% CI 1.41-3.89). A corrected meta-analysis that combined atomoxetine and methylphenidate did not find a statistically significant increase. MotherToBaby says studies have not been done to assess miscarriage risk, and the STRATTERA label says published studies are insufficient to establish a drug-associated risk. The atomoxetine-specific study was published after the MotherToBaby statement may have been prepared, and it used filled prescriptions rather than confirmed use. The corrected meta-analysis pooled atomoxetine with methylphenidate and used a different population and comparison group. The PubMed abstract still displays its pre-correction estimate; the corrected PMC full text reports the updated estimates. The newer atomoxetine-specific study is a signal that should be reported, but it is observational and does not establish cause. The corrected pooled estimates are not statistically significant and do not provide an atomoxetine-only result. The evidence supports provider guidance, not a conclusion that atomoxetine must be avoided.

Atomoxetine

Atomoxetine — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications